Cooper Companies (NASDAQ:COO) Director Lawrence Erik Kurzius Purchases 10,000 Shares

Key Points

• Director Lawrence Kurzius bought 10,000 Cooper Companies shares for approximately $549,300, increasing his holdings by 47.4% to 31,099 shares. He also purchased another 10,000 shares earlier in the week.
• Cooper Companies reported quarterly EPS of $1.15, exceeding the $1.12 analyst consensus, while revenue of $1.07 billion fell short of estimates. The board also authorized a $3 billion share-repurchase program.
• The stock traded near $53.78, close to its 52-week low, amid concerns over channel inventory reductions and lowered fiscal 2026 guidance. Analysts’ consensus rating is Hold, with an average price target of $71.47.

The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) Director Lawrence Kurzius acquired 10,000 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an average price of $54.93 per share, for a total transaction of $549,300.00. Following the completion of the transaction, the director owned 31,099 shares in the company, valued at $1,708,268.07. The trade was a 47.40% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 14th, Lawrence Kurzius bought 10,000 shares of Cooper Companies stock. The stock was purchased at an average price of $53.91 per share, with a total value of $539,100.00.

Cooper Companies Stock Performance

Shares of NASDAQ:COO traded down $0.83 during trading hours on Thursday, hitting $53.78. The stock had a trading volume of 5,582,704 shares, compared to its average volume of 2,534,851. The stock's fifty day simple moving average is $70.58 and its 200 day simple moving average is $68.98. The firm has a market capitalization of $10.23 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 2.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the company posted $0.49 EPS. The business's revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has initiated a stock buyback program on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.

Institutional Trading of Cooper Companies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. HBK Investments L P acquired a new stake in shares of Cooper Companies in the second quarter valued at $31,666,000. Sequoia Financial Advisors LLC grew its holdings in Cooper Companies by 290.4% during the second quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company's stock worth $2,459,000 after acquiring an additional 25,504 shares during the period. Tidal Investments LLC raised its position in Cooper Companies by 281.4% in the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company's stock worth $5,945,000 after acquiring an additional 61,165 shares in the last quarter. National Pension Service lifted its holdings in Cooper Companies by 9,314.0% in the 2nd quarter. National Pension Service now owns 526,149 shares of the medical device company's stock valued at $37,730,000 after acquiring an additional 520,560 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its holdings in Cooper Companies by 379.0% in the 2nd quarter. WINTON GROUP Ltd now owns 42,483 shares of the medical device company's stock valued at $3,046,000 after acquiring an additional 33,613 shares during the last quarter. Institutional investors own 24.39% of the company's stock.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Several directors bought Cooper Companies shares after the selloff, including Paul Keel, Lawrence Kurzius, and Walter Rosebrough Jr., who collectively purchased roughly $1.33 million of stock. The insider buying may signal that management and board members view the recent decline as excessive. Insider purchase reports
• Positive Sentiment: The company’s $1.15 adjusted earnings per share exceeded the $1.12 consensus estimate, and its board authorized a $3 billion share-repurchase program. These factors could provide longer-term support if operating performance stabilizes. Cooper Companies financial information
• Neutral Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Cooper Companies investors. Similar investigations were also announced by Bragar Eagel & Squire and Levi & Korsinsky. The announcements do not establish wrongdoing, but they add legal and headline risk. Pomerantz investigation announcement
• Negative Sentiment: Investors remain concerned about U.S. channel inventory reductions, or destocking, revealed with the third-quarter results. The issue raises questions about near-term sales momentum and how quickly distributor inventories will normalize. HBSS inventory report
• Negative Sentiment: Cooper Companies lowered its fiscal 2026 revenue outlook to approximately $4.23–$4.25 billion from $4.29–$4.32 billion and reduced adjusted EPS guidance to $4.51–$4.55 from $4.58–$4.66. The cuts reflect softer contact-lens demand, particularly at CooperVision, and have prompted analysts to lower valuation targets. Levi and Korsinsky announcement

Analyst Ratings Changes

Several research firms recently weighed in on COO. William Blair downgraded shares of Cooper Companies from an "outperform" rating to a "market perform" rating in a report on Thursday, September 10th. KeyCorp reissued a "sector weight" rating on shares of Cooper Companies in a research note on Friday, June 5th. Wells Fargo & Company set a $61.00 price target on shares of Cooper Companies and gave the stock an "equal weight" rating in a research report on Thursday, September 10th. Wall Street Zen lowered shares of Cooper Companies from a "buy" rating to a "hold" rating in a research note on Saturday, September 12th. Finally, UBS Group decreased their price objective on shares of Cooper Companies from $75.00 to $66.00 and set a "neutral" rating for the company in a report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.